title: Effects of fibric acid derivatives on biliary lipid composition.
abstract: Fenofibrate, a potent analogue of clofibrate, causes changes in biliary lipid composition similar to those seen with clofibrate and other derivatives of fibric acid, although there is a suggestion that the increase in cholesterol content may be accompanied by an increase in phospholipid content as well as a decrease in bile acid content. This may favor liquid crystal formation, and fenofibrate may have less propensity to cause gallstones than would other derivatives. Many other factors are also important in determining whether supersaturated bile will result in gallstone formation, and the use of this compound should be monitored in the future to determine the clinical importance of these findings.
authors.affiliation: Columbia University College of Physicians and Surgeons, New York, New York.
authors.forename: R H
authors.initials: RH
authors.lastname: Palmer
mesh_terms: D001629:Bezafibrate / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D058607:Fibric Acids; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D011422:Propionates / Q000627:therapeutic use*; D011897:Random Allocation
chemical_list: D058607:Fibric Acids; D000960:Hypolipidemic Agents; D011422:Propionates; C009746:etofibrate; D002995:Clofibric Acid; C019304:ciprofibrate; D002994:Clofibrate; D011345:Fenofibrate; D001629:Bezafibrate